安罗替尼治疗恶性肿瘤的不良反应分析★

Adverse reaction of anlotinib in the treatment of malignant tumors★

摘要:

目的 了解安罗替尼（AL3818）的安全性，以便更好地应用该药，为患者提供更安全、有效的治疗。方法 收集安罗替尼在临床应用中的常见不良反应信息，结合现有的临床数据，对比安罗替尼与同类抗肿瘤药物的不良反应类型及发生率的差别。结果 安罗替尼的不良反应主要为食欲减退、乏力、蛋白尿、血尿、腹痛、呕吐、腹泻、高血压和手足综合征等，其中1级、2级不良反应78例（96.30%），3级不良反应3例（3.70%）。与同类抗肿瘤药物相比，安罗替尼的出血、高血压、蛋白尿等不良反应发生率明显低于阿帕替尼和贝伐珠单抗，差异均具有统计学意义（P<0.05）。结论 盐酸安罗替尼胶囊用于治疗恶性肿瘤安全性较高。

Abstract:

Objective To understand the safety of anlotinib (AL3818) in order to provide safer and more effective treatment for patients.Methods The common adverse reactions of anlotinib in clinical application were collected, and the differences in the types and incidences of adverse reactions were compared between anlotinib and similar antitumor drugs according to the existing clinical data.Results The adverse reactions of anlotinib mainly included anorexia, fatigue, proteinuria, hematuria, abdominal pain, vomiting, diarrhea, hypertension and hand-foot syndrome, among which 78 cases (96.30%) had grade 1 and grade 2 adverse reactions and 3 cases (3.70%) had grade 3 adverse reactions. Compared with similar antitumor drugs, the incidence of adverse reactions such as bleeding, thrombosis, hypertension and proteinuria of allotinib was significantly lower than that of apatinib and bevacizumab, and the difference was statistically significant (P<0.05).Conclusion Anlotinib hydrochloride capsule is safe in the treatment of malignant tumor.